

## DAFTAR PUSTAKA

- Afifah, R., Wintoko, R., & Ismunandar, H. (2022). Peritonitis Bakterialis Spontan pada Pasien Sirosis Hepatik: Literatur Review. *Medula*, *12*, 495–499.
- Ahmed, Z., Ahmed, U., Walayat, S., Ren, J., Martin, D. K., Moole, H., Koppe, S., Yong, S., & Dhillon, S. (2018). Liver function tests in identifying patients with liver disease. *Clinical and Experimental Gastroenterology*, *11*, 301–307. <https://doi.org/10.2147/CEG.S160537>
- Ainun, J., Fendy Dwimartyono, Mulyadi, F. E., Reeny Purnamasari, Sommeng, F., Wahab, M. I., Kuswardhana, H., Arsyad, N. N., & Muhammad Imran. (2022). Pola Penggunaan Analgesik Pasien Bedah Orthopedi di Ruang Gawat Darurat Rs. Ibnu Sina Makassar. *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*, *2*(7), 496–503. <https://doi.org/10.33096/fmj.v2i7.99>
- Albillos, A., & Krag, A. (2023). Beta-blockers in the era of precision medicine in patients with cirrhosis. *Journal of Hepatology*, *78*(4), 866–872. <https://doi.org/10.1016/j.jhep.2022.12.005>
- Aldora, G. S. (2022). *Drug-induced Liver Injury pada Pasien Rawat Inap di Rumah Sakit Universitas Indonesia Tahun 2021*. (Skripsi Sarjana, Universitas Indonesia). <https://lib.ui.ac.id/m/detail.jsp?id=20521045&lokasi=lokal#parentHorizontalTab1>.
- Amalia, M., Hidayati, P. H., Eka Yanti, A. K., Vitayani, S., & Gayatri, S. W. (2023). Karakteristik Pasien Sirosis Hepatis. *UMI Medical Journal*, *8*(1), 53–61. <https://doi.org/10.33096/umj.v8i1.244>
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. *Journal of Hepatology*, *70*(6), 1222–1261. <https://doi.org/10.1016/j.jhep.2019.02.014>
- Anindyaguna, A., Mustofa, S., Anggraini, D. I., & Oktarlina, R. Z. (2022). Drug-Induced Liver Injury Akibat Penyalahgunaan Parasetamol. *Medula*, *12*(3), 500–507.
- Ardiani, T., & Azmi, R. N. (2021). Identifikasi Kejadian Hepatotoksik Pada Pasien Tuberkulosis Dengan Penggunaan Obat Anti Tuberkulosis di Rumah Sakit Umum Daerah Abdul Wahab Sjahrani. *Borneo Student Research*, *3*(1), 2021.
- Barrett, K. E., Barman, S. M., Boitano, S., & Brooks, H. I. (2012). *Ganong Buku ajar Fisiologi Ganong Fisiologi Kedokteran* (24th ed.). ECG. Jakarta.

- Björnsson, E. S. (2016). Hepatotoxicity by drugs: The most common implicated agents. *International Journal of Molecular Sciences*, 17(2). <https://doi.org/10.3390/ijms17020224>
- Chisholm-Burns, M. A., Schwinghammer, T. L., Malone, P. M., Kolesar, J. M., Lee, K. C., & Brandon Bookstaver, L. (2019). *Pharmacotherapy Principles and Practice* (5th ed.). Mc Graw-Hill Companies. New York.
- Dewi, T., Masruhim, M. A., & Sulistiarini, R. (2016). Identifikasi Obat Penginduksi Kerusakan Hati Pada Pasien Hepatitis Di Rumah Sakit Abdul Wahab Sjahranie. *April*, 151–157. <https://doi.org/10.25026/mpc.v3i1.78>
- Efmisa, A. K., Armenia, & Almasdy, D. (2023). Penggunaan Obat Berpotensi Hepatotoksik Pada Pasien Sirosis Hati: Suatu Telaahan. *Journal of Pharmaceutical and Sciences*, 6(2), 766–771.
- Fadyla, R. M., Bakhtiar, R., & Murti, R. I. S. (2021). Jurnal Sains dan Kesehatan. *Jurnal Sains Dan Kesehatan*, 3(4), 404–410.
- Gede Juliarta, I., Kadek Mulyantari, N., Putu, W., & Yasa, S. (2018). Gambaran Hepatotoksisitas (Alt/Ast) Penggunaan Obat Anti Tuberkulosis Lini Pertama Dalam Pengobatan Pasien Tuberkulosis Paru Rawat Inap Di Rsup Sanglah Denpasar Tahun 2014. *E-Jurnal Medika Udayana*, 7(10), 2303–1395. <http://ojs.unud.ac.id/index.php/eum>
- Geong, G. Y., Kang, S. H., & Lee, C. M. (2019). An updated review on the epidemiology, pathophysiology, etiology, and diagnosis of liver cirrhosis. *J Gastroenterol*, 593–619. <https://www.researchgate.net/publication/331752269>
- Giordano, C. M., & Zervos, X. B. (2013). Clinical manifestations and treatment of drug-induced hepatotoxicity. *Clinics in Liver Disease*, 17(4), 565–573. <https://doi.org/10.1016/j.cld.2013.07.003>
- Gracie, D. J., & Ford, A. C. (2016). The possible risks of proton pump inhibitors: These drugs have revolutionised the management of gastrointestinal diseases, but their long term use may have risks. *Medical Journal of Australia*, 205(7), 292–294. <https://doi.org/10.5694/mja16.00750>
- Gupta, S., & Walker, S. (2021). Testing for cirrhosis. *Australian Prescriber*, 44(6), 197–199. <https://doi.org/10.18773/austprescr.2021.053>
- Hakimah, E. N. (2016). Pengaruh Kesadaran Merek, Persepsi Kualitas, Asosiasi Merek, Loyalitas Merek Terhadap Keputusan Pembelian Makanan Khas Daerah Kediri Tahu Merek “POO” Pada Pengunjung Toko Pusat Oleh-Oleh Kota Kediri. *Jurnal Nusantara Aplikasi Manajemen Bisnis*, 1(1), 13–21.
- Hamzah Pratama. (2017). Tatalaksana Primary Biliary Cirrhosis. *Ckd*, 44(1), 24–27.

- Hardianto, D. (2021). Insulin: Production, Types, Analysis, and Routes of Delivery. *Jurnal Bioteknologi & Biosains Indonesia*, 8(2), 321–331. <http://ejurnal.bppt.go.id/index.php/JBBI>
- Heidet, M., Amathieu, R., Audureau, E., Augusto, O., Nicolazo De Barmon, V., Rialland, A., Schmitz, D., Pierrang, F., Marty, J., Chollet-Xémard, C., Thirion, O., & Jacob, L. (2018). Efficacy and tolerance of early administration of tranexamic acid in patients with cirrhosis presenting with acute upper gastrointestinal bleeding: A study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (the EXARHOSE study). *BMJ Open*, 8(8), 1–10. <https://doi.org/10.1136/bmjopen-2018-021943>
- Huang, D. Q., Terrault, N. A., Tacke, F., Glud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023). Global epidemiology of cirrhosis — aetiology, trends and predictions. *Nature Reviews Gastroenterology and Hepatology*, 20(6), 388–398. <https://doi.org/10.1038/s41575-023-00759-2>
- Kang, S. M., & Song, J. E. (2018). Ceftriaxone-Induced Acute Pancreatitis in Patient with Liver Abscess. *The Korean Journal of Pancreas and Biliary Tract*, 23(2), 82–86. <https://doi.org/10.15279/kpba.2018.23.2.82>
- Kaplan, A., & Rosenblatt, R. (2022). Symptom Management in Patients with Cirrhosis: a Practical Guide. *Current Treatment Options in Gastroenterology*, 20(2), 144–159. <https://doi.org/10.1007/s11938-022-00377-y>
- Katarey, D., & Verma, S. (2016). Drug-induced liver injury (DILI). *Clinical Medicine*, 16(6), s104–s109. <https://doi.org/10.1007/s15006-019-0458-z>
- Katzung, B. G. (2018). *Basic and Clinical Pharmacology* (14th ed.). McGraw-Hill Education. San Francisco.
- Kemenkes RI. (2018). *Klasifikasi Obesitas Setelah Pengukuran IMT*. Kementerian Kesehatan Republik Indonesia. Terdapat di: <https://p2ptm.kemkes.go.id/infographic-p2ptm/obesitas/klasifikasi-obesitas-setelah-pengukuran-imt> [Diakses pada 17 Desember 2023].
- Kemenkes RI. (2021). *Keputusan Menteri Kesehatan RI HK.01.07/MENKES/6477/2021 Tentang Daftar Obat Esensial Nasional*.
- Kemenkes RI. (2023). *Kelompok Usia*. Kementerian Kesehatan Republik Indonesia. Terdapat di: <https://ayosehat.kemkes.go.id/kategori-usia/dewasa> [Diakses pada 17 Desember 2023].
- Kotsuka, M., Hashimoto, Y., Nakatake, R., Okuyama, T., Hatta, M., Yoshida, T., Okumura, T., Nishizawa, M., Kaibori, M., & Sekimoto, M. (2022). Omeprazole Increases Survival through the Inhibition of Inflammatory Mediators in Two Rat

Sepsis Models. *Shock*, 57(3), 444–456.  
<https://doi.org/10.1097/SHK.0000000000001897>

Kundharindi, B., Ibrahim, A., & Ayu, W. D. (2016). *Karakteristik dan Pola Pengobatan Diuretik pada Pasien Asites di Rawat Inap Rumah Sakit Islam Samarinda Tahun Periode Januari-Desember 2015*. 3.

LiverTox. (2017). *Propranolol*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease). Terdapat di: <https://www.ncbi.nlm.nih.gov/books/NBK548218/> [Diakses pada 6 Mei 2024].

LiverTox. (2018a). *Insulin*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease). Terdapat di: <https://www.ncbi.nlm.nih.gov/books/NBK548016/> [Diakses pada 2 Mei 2024].

LiverTox. (2018b). *Ketorolac*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease). Terdapat di: <https://www.ncbi.nlm.nih.gov/books/NBK548459/> [Diakses pada 2 Mei 2024].

LiverTox. (2019a). *Categorization Of The Likelihood Of Drug Induced Liver Injury*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease). Terdapat di: <https://www.ncbi.nlm.nih.gov/books/NBK548392/> [Diakses pada 22 November 2023].

LiverTox. (2019b). *Omeprazole*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease). Terdapat di: <https://www.ncbi.nlm.nih.gov/books/NBK548771/> [Diakses pada 6 Mei 2024]

LiverTox. (2021). *Spiroinolactone*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease). Terdapat di: <https://www.ncbi.nlm.nih.gov/books/NBK547921/> [Diakses pada 6 Mei 2024].

Lovena, A., Miro, S., & Efrida, E. (2017). Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*, 6(1), 5. <https://doi.org/10.25077/jka.v6i1.636>

Maharani, B. N. P., Hendriani, A. D., & Iswari, P. W. P. (2023). Liver Cirrhosis: Pathophysiology, Diagnosis, and Management. *Jurnal Biologi Tropis*, 23(1), 457–463. <https://doi.org/10.29303/jbt.v23i1.5763>

Maharani, S., Efendi, D., & Tampubolon, L. A. (2019). Gambaran Pemeriksaan Fungsi Hati pada Pasien Sirosis Hepatis yang Dirawat di Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau Periode 2013 - 2015. *Jurnal Ilmu Kedokteran (Journal of Medical Science)*, 12(1), 46. <https://doi.org/10.26891/jik.v12i1.2018.46-51>

- Mansour, D., & McPherson, S. (2018). Management of decompensated cirrhosis. *Clinical Medicine, Journal of the Royal College of Physicians of London*, 18(2), s60–s65. <https://doi.org/10.7861/clinmedicine.18-2-s60>
- Manurung, S. G., Sopacua, E., & Tanamal, C. (2021). *Gambaran Gatroscopy Pada Pasien Sirosis Hati Di RSUD Royal Prima Medan Dari 1 Januari 2019 - 31 Desember 2019*. 6(1), 109–113.
- Martini, F. H., Nath, J. L., & Bartholomew, E. F. (2018). *Fundamentals of Anatomy & Physiology* (11th ed.). Pearson Education. San Francisco. <https://doi.org/10.2307/3413425>
- Milan, Z., & Goonasekera, C. (2021). *Anesthesia for Hepatico-Pancreatic-Biliary Surgery and Transplantation*. Springer. [https://doi.org/10.1007/978-3-030-51331-3\\_24](https://doi.org/10.1007/978-3-030-51331-3_24)
- Mohammadnejad, L., Soltaninejad, K., Seyedabadi, M., Pouri, S. K. G., Shokrzadeh, M., & Mohammadi, H. (2021). Evaluation of mitochondrial dysfunction due to oxidative stress in therapeutic, toxic and lethal concentrations of tramadol. *Toxicology Research*, 10(6), 1162–1170. <https://doi.org/10.1093/toxres/tfab096>
- Munz, M., Grummich, H., Birkmann, J., Wilhelm, M., Holzgrabe, U., & Sörgel, F. (2017). Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature. *Chemotherapy*, 62(6), 367–373. <https://doi.org/10.1159/000480399>
- Muslim, Z., Novrianti, A., Irnamera, D., Kemenkes Bengkulu, P., Nomor, J. I., Harapan, P., & Bengkulu, K. (2020). Resistance Test of Bacterial Causes of Urinary Tract Infection Against Ciprofloxacin and Ceftriaxone Antibiotics. *Jurnal Teknologi Dan Seni Kesehatan*, 11(2), 203–212. <https://doi.org/10.36525/sanitas.2020.19>
- Muti, A. F., & Anindya, C. (2021). Analysis of Potential Drug-drug Interactions in Liver Cirrhosis Patients. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal)*, 7(1), 17–28. <https://doi.org/10.22487/j24428744.2021.v7.i1.15148>
- Newsome, P. N., Cramb, R., Davison, S. M., Dillon, J. F., Foulerton, M., Godfrey, E. M., Hall, R., Harrower, U., Hudson, M., Langford, A., MacKie, A., Mitchell-Thain, R., Sennett, K., Sheron, N. C., Verne, J., Walmsley, M., & Yeoman, A. (2018). Guidelines on the management of abnormal liver blood tests. *Gut*, 67(1), 6–19. <https://doi.org/10.1136/gutjnl-2017-314924>
- NIDDK. (2023). *Cirrhosis*. National Institute of Diabetes and Digestive and Kidney Disease. Terdapat di: <https://www.niddk.nih.gov/health-information/liver-disease/cirrhosis> [Diakses pada 22 November 2023].

- Nishida, T. (2017). Diagnosis and clinical implications of diabetes in liver cirrhosis: A focus on the oral glucose tolerance test. *Journal of the Endocrine Society*, *1*(7), 886–896. <https://doi.org/10.1210/js.2017-00183>
- Nishikawa, H., & Osaki, Y. (2015). Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. *Mediators of Inflammation*, *2015*. <https://doi.org/10.1155/2015/872152>
- Novitasari, A. E., Rosidah, & Farihah, N. (2021). Analisis Kadar SGPT dan SGOT Pengemudi Ojek Online yang Terpapar Asap Kendaraan Bermotor. *Journals of Ners Community*, *12*(1), 114–119. <https://journal.unigres.ac.id/index.php/JNC/article/view/1363>
- Nurissyita, A. M.-. (2021). Efektivitas Penggunaan Asam Traneksamat Oral Pada Pasien Melasma. *Jurnal Ilmiah Kesehatan Media Husada*, *10*(2), 99–108. <https://doi.org/10.33475/jikmh.v10i2.260>
- Oktaviani, E., Indriani, L., & Wulandari, H. (2022). Profil Kontrol Glikemik Antidiabetik pada Pasien DM Tipe 2 dengan Sirosis Hati. *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, *12*(1), 1–13. <https://doi.org/10.22146/jmpf.68075>
- Otto, A. O., Rivera, C. G., Zeuli, J. D., & Temesgen, Z. (2021). Hepatotoxicity of contemporary antiretroviral drugs. *Cells*, *10*. <https://doi.org/10.1097/COH.0000000000000706>
- Paniagua, A. C., & Amariles, P. (2018). Hepatotoxicity by Drugs. *Pharmacokinetics and Adverse Effects of Drugs - Mechanisms and Risks Factors*. <https://doi.org/10.5772/intechopen.72005>
- Papazafiropoulou, A., & Melidonis, A. (2019). Antidiabetic Agents in Patients with Hepatic Impairment. *World Journal of Meta-Analysis*, *7*(8), 380–388.
- Priantoro, H. (2017). Hubungan Beban Kerja Dan Lingkungan Kerja Dengan Kejadian Burnout Perawat Dalam Menangani Pasien Bpjs. *Jurnal Ilmiah Kesehatan*, *16*(3), 9–16. <https://doi.org/10.33221/jikes.v16i3.33>
- Purwanto, T., & Sangging, P. R. A. (2023). Etiologi, patofisiologi, evaluasi, dan tatalaksana drug induced hepatotoxicity. *Medula*, *13*(3), 322–326. <https://journalofmedula.com/index.php/medula/article/download/636/510>
- Ramappa, V., & Aithal, G. P. (2013). Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *Journal of Clinical and Experimental Hepatology*, *3*(1), 37–49. <https://doi.org/10.1016/j.jceh.2012.12.001>
- Robiyanto, R., Liana, J., & Purwanti, N. U. (2019). Kejadian Obat-Obatan Penginduksi Kerusakan Liver pada Pasien Sirosis Rawat Inap di RSUD Dokter

- Soedarso Kalimantan Barat. *Jurnal Sains Farmasi & Klinis*, 6(3), 274. <https://doi.org/10.25077/jsfk.6.3.274-285.2019>
- Rosida, A. (2016). Pemeriksaan Laboratorium Penyakit Hati. *Berkala Kedokteran*, 12(1), 123–131. [https://doi.org/10.5005/jp/books/10446\\_15](https://doi.org/10.5005/jp/books/10446_15)
- Runyon, B. A. (2013). Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. *Hepatology*, 57(4), 1651–1653. <https://doi.org/10.1002/hep.26359>
- Saleem, S., Katragadda, R., Weissman, S., & Bleibel, W. (2019). Morbidity and mortality of infections in the cirrhotic patients: a US population-based study Comparison of ISG15, IL28B and USP18 mRNA levels in peripheral blood mononuclear cells of chronic hepatitis B virus infected patients and healthy individuals *Morb. Gastroenterol Hepatol Bed Bench*, 12(3), 233–238.
- Sari, M. ., Cahaya, N., & Susilo, Y. H. (2020). Studi Penggunaan Obat Golongan Beta-Blocker Pada Pasien Rawat Inap Rumah Sakit Ansari Saleh Banjarmasin. *Jurnal Farmasi Udayana*, 9(2), 123–133. <https://doi.org/10.24843/jfu.2020.v09.i02.p07>
- Saskara, P. M. A., & Suryadarma, I. (2018). Laporan Kasus : Sirosis Hepatis. *FK Universitas Udayana*, 1–20.
- Sepanlou, S. G., Safiri, S., Bisignano, C., Ikuta, K. S., Merat, S., Saberifiroozi, M., Poustchi, H., Tsoi, D., Colombara, D. V., Abdoli, A., Adedoyin, R. A., Afarideh, M., Agrawal, S., Ahmad, S., Ahmadian, E., Ahmadpour, E., Akinyemiju, T., Akunna, C. J., Alipour, V., ... Malekzadeh, R. (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet Gastroenterology and Hepatology*, 5(3), 245–266. [https://doi.org/10.1016/S2468-1253\(19\)30349-8](https://doi.org/10.1016/S2468-1253(19)30349-8)
- Shehu, A. I., Ma, X., & Venkataramanan, R. (2017). Mechanisms of Drug-Induced Hepatotoxicity. *Clinics in Liver Disease*, 21(1), 35–54. <https://doi.org/10.1016/j.cld.2016.08.002>
- Shetty, A., Yum, J. J., & Saab, S. (2019). The gastroenterologist’s guide to preventive management of compensated cirrhosis. *Gastroenterology and Hepatology*, 15(8), 423–430.
- Suh, J. I. (2020). Drug-induced liver injury. *Yeungnam University Journal of Medicine*, 37(1), 2–12.

- Sujana, K. S., & Maulida, M. (2021). Efektivitas N-Acetylsistein pada Pasien COVID-19. *Cermin Dunia Kedokteran*, 48(7), 416–418. <https://doi.org/10.55175/cdk.v48i7.99>
- Sulistiyoningrum, E., & Murtisiwi, L. (2019). Gambaran Peresepan Pasien Sirosis Hati di Instalasi Rawat Jalan Rumah Sakit Panti Waluyo Surakarta. *Journal of Pharmacy*, 9(1), 1–7.
- Tenório, M. C. D. S., Graciliano, N. G., Moura, F. A., de Oliveira, A. C. M., & Goulart, M. O. F. (2021). N-acetylcysteine (NAC): Impacts on Human Health. *Antioxidants*, 10(6).
- Thaha, R., Yunita, E., & Sabir, M. (2020). Sirosis Hepatis. *Jurnal Medical Profession (MedPro)*, 2(3), 166–175.
- Toapanta-Yanchapaxi, L., Guering, E. L., & García-Juárez, I. (2018). Atypical abdominal pain in a patient with liver cirrhosis. *Annals of Hepatology*, 17(1), 162–164. <https://doi.org/10.5604/01.3001.0010.7548>
- Verma, S., Midha, M., & Bhadoria, A. S. (2020). Facts and Figures on Medical Record Management from a Multi Super Specialty Hospital in Delhi NCR: A Descriptive Analysis. *Journal of Family Medicine and Primary Care*, 9(1), 418–423. <https://doi.org/10.4103/jfmpc.jfmpc>
- Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*, 60(2), 715–735. <https://doi.org/10.1002/hep.27210>
- Virgonita, S., & Zulkarnain, A. K. (2012). Pola Penggunaan Obat pada Pasien Sirosis Hati di Instalasi Rawat Inap Bangsal Penyakit Dalam Rumah Sakit Dr. Sardjito Yogyakarta. *Majalah Farmasuetik*, 8(3), 218–226.
- Virma, S. G., Adelin, P., & Mona, L. (2023). Karakteristik Pasien Sirosis Hepatis di Rumah Sakit Dr. Achmad Mochtar Bukittinggi. *Jurnal Kedokteran Nanggroe Medika*, 6(1), 1–8.
- WHO. (2016). Liver Cirrhosis, Age-standardized death rates (15+), per 100.000 population. Global Health Observatory. Terdapat di: [https://www.who.int/data/gho/data/indicators/indicator-details/GHO/liver-cirrhosis-age-standardized-death-rates-\(15-\)-per-100-000-population](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/liver-cirrhosis-age-standardized-death-rates-(15-)-per-100-000-population) [Diakses pada 11 Oktober 2023].
- Woodhead, J. L., Yang, K., Oldach, D., MacLauchlin, C., Fernandes, P., Watkins, P. B., Siler, S. Q., & Howell, B. A. (2019). Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems



- Toxicology Modeling. *Pharmaceutical Research*, 36(3).  
<https://doi.org/10.1007/s11095-019-2582-y>
- Xiao, S., Xie, W., Zhang, Y., Lei, L., & Pan, Y. (2023). Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019. *Annals of Medicine*, 55(2).  
<https://doi.org/10.1080/07853890.2023.2252326>
- Yin, Y., Li, Y., Shao, L., Yuan, S., Liu, B., Lin, S., Yang, Y., Tang, S., Meng, F., Wu, Y., Chen, Y., Li, B., Zhu, Q., & Qi, X. (2021). Effect of Body Mass Index on the Prognosis of Liver Cirrhosis. *Frontiers in Nutrition*, 8(August).  
<https://doi.org/10.3389/fnut.2021.700132>
- Yoshiji, H., Nagoshi, S., Akahane, T., Asaoka, Y., Ueno, Y., Ogawa, K., Kawaguchi, T., Kurosaki, M., Sakaida, I., Shimizu, M., Taniyai, M., Terai, S., Nishikawa, H., Hiasa, Y., Hidaka, H., Miwa, H., Chayama, K., Enomoto, N., Shimosegawa, T., ... Koike, K. (2021). Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. *Journal of Gastroenterology*, 56(7), 593–619.  
<https://doi.org/10.1007/s00535-021-01788-x>
- Zelege, A., Misiker, B., & Yesuf, T. A. (2020). Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia. *BMC Research Notes*, 13(1), 1–5. <https://doi.org/10.1186/s13104-019-4872-1>
- Zulhadji, F. M., Ambar, E., & Armaidj, L. (2023). Karakteristik Pasien Sirosis Hepatis di RSUD Dr. H. Chasan Boesoirie Ternate. *E-Jurnal Medika Udayana*, 12(9), 96–100. <https://doi.org/10.24843/mu.2023.v12.i09.p17>